3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Conditions
Ovarian Neoplasms
40
Breast Neoplasms
12
Prostatic Neoplasms
11
Fallopian Tube Neoplasms
10
Pancreatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
7
Glioblastoma
6
Neoplasm Metastasis
5
Carcinoma, Ovarian Epithelial
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Glioma
4
Small Cell Lung Carcinoma
3
Mesothelioma
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Interventions
Cisplatin
21
pembrolizumab
16
Gemcitabine
16
Paclitaxel
15
Radiotherapy
14
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
9
Cetuximab
9
Magnetic Resonance Spectroscopy
8
Radiation
7
padeliporfin
6
Specimen Handling
6
Oxaliplatin
6
Fluorouracil
6
Drug Therapy
6
Docetaxel
6
Capecitabine
6
Bevacizumab
6
anlotinib
5
Nivolumab
5
Irinotecan
5
Erlotinib Hydrochloride
5
Celecoxib
5
poly ICLC
4
fludarabine
4
Standard of Care
4
Sorafenib
4
Leucovorin
4
Ipilimumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma
×
niraparib
×
Clear all
NCT06827353
2025-02-14
OVNI-B
Centre Hospitalier Universitaire de NÄ«mes
Recruiting
300 enrolled
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled